27994293|t|Expression IRF / MUM1 >25% Predictor to Three- year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
27994293|a|Non Hodgkin lymphoma - Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results. achieving the estimated three- year survival and influence of IRF / MUM1 expression to three- year survival. A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4 / MUM1, CD 138. Included the GCB type was 65%. Impact prognostic index IPI >2 GBC vs non GBC p=0,038 X(2). Statistically significant difference was confirmed compared to the IPI > 2 to 3 year OS p<0,0005 X(2). Significantly longer three- year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X(2). Clinical and immunohistochemical factors showed a significant impact to three- year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three- year survival. expression MUM1 >25% has the greatest impact on the disease outcome - three- year survival.
27994293	0	10	Expression	T045	C1171362
27994293	11	14	IRF	T116,T123	C1564741
27994293	17	21	MUM1	T116,T123	C0299544
27994293	27	36	Predictor	T078	C2698872
27994293	47	51	year	T079	C0439234
27994293	52	60	Survival	T052	C0038952
27994293	64	93	Diffuse Large B Cell Lymphoma	T191	C0079744
27994293	101	119	Immunochemotherapy	T061	C4087148
27994293	124	144	Non Hodgkin lymphoma	T191	C0024305
27994293	147	176	Diffuse large B cell lymphoma	T191	C0079744
27994293	178	182	DLBC	T191	C0079744
27994293	204	213	varieties	T077	C2346866
27994293	221	228	disease	T047	C0012634
27994293	230	238	Analysis	T062	C0936012
27994293	276	306	characteristics of the disease	T046	C0599878
27994293	323	331	clinical	T201	C0683325
27994293	333	352	immunohistochemical	T059	C1441616
27994293	354	365	cytogenetic	T033	C4055168
27994293	370	379	molecular	T080	C1521991
27994293	380	395	characteristics	T080	C1521970
27994293	400	407	improve	T033	C0184511
27994293	408	417	treatment	T169	C0039798
27994293	418	425	results	T169	C1274040
27994293	458	462	year	T079	C0439234
27994293	463	471	survival	T052	C0038952
27994293	489	492	IRF	T116,T123	C1564741
27994293	495	499	MUM1	T116,T123	C0299544
27994293	500	510	expression	T045	C1171362
27994293	521	525	year	T079	C0439234
27994293	526	534	survival	T052	C0038952
27994293	538	573	study was retrospective-prospective	UnknownType	C0681849
27994293	575	583	patients	T101	C0030705
27994293	608	613	years	T079	C0439234
27994293	616	622	period	T079	C1948053
27994293	636	641	study	T062	C2603343
27994293	654	662	patients	T101	C0030705
27994293	663	670	de novo	T078	C1515568
27994293	671	676	DLBCL	T191	C0079744
27994293	678	681	Age	T032	C0001779
27994293	692	697	years	T079	C0439234
27994293	707	714	average	T081	C1510992
27994293	715	718	age	T032	C0001779
27994293	722	727	years	T079	C0439234
27994293	729	733	male	T032	C0086582
27994293	749	755	female	T032	C0086287
27994293	768	774	Median	T082	C2939193
27994293	775	784	follow-up	T033	C0260832
27994293	792	798	months	T079	C0439231
27994293	805	811	months	T079	C0439231
27994293	827	842	differentiation	T129	C0003324
27994293	843	858	immunophenotype	T059	C0079611
27994293	859	869	antibodies	T116,T129	C0003241
27994293	886	895	anti-CD20	T116,T129	C3891557
27994293	897	906	anti-CD10	T116,T129	C3900024
27994293	908	918	anti-Bcl-6	T116,T129	C0003241
27994293	920	925	IRF-4	T116,T123	C0299544
27994293	928	932	MUM1	T116,T123	C0299544
27994293	934	940	CD 138	T116,T123	C1609943
27994293	955	963	GCB type	T191	C1333295
27994293	973	996	Impact prognostic index	T170	C1512894
27994293	997	1000	IPI	T170	C1512894
27994293	1004	1007	GBC	T191	C1333295
27994293	1011	1014	non	T033	C1513916
27994293	1015	1018	GBC	T191	C1333295
27994293	1033	1058	Statistically significant	T081	C0237881
27994293	1059	1069	difference	T081	C1705241
27994293	1084	1092	compared	T052	C1707455
27994293	1100	1103	IPI	T170	C1512894
27994293	1113	1117	year	T079	C0439234
27994293	1164	1168	year	T079	C0439234
27994293	1169	1177	survival	T052	C0038952
27994293	1204	1207	GCB	T191	C1333295
27994293	1227	1230	GCB	T191	C1333295
27994293	1255	1263	Clinical	T201	C0683325
27994293	1268	1295	immunohistochemical factors	T080	C0205556
27994293	1305	1323	significant impact	T080	C4049986
27994293	1334	1338	year	T079	C0439234
27994293	1339	1347	survival	T052	C0038952
27994293	1351	1361	univariate	T062	C0683962
27994293	1363	1366	LDH	T116,T126	C0022917
27994293	1376	1380	MUM1	T116,T123	C0299544
27994293	1396	1400	CD10	T116,T126	C0025250
27994293	1439	1449	borderline	T080	C0205189
27994293	1464	1485	multivariate analysis	T081	C0026777
27994293	1487	1497	expression	T045	C1171362
27994293	1498	1502	MUM1	T116,T123	C0299544
27994293	1520	1526	impact	T080	C4049986
27994293	1572	1587	disease outcome	T033	C0679250
27994293	1597	1601	year	T079	C0439234
27994293	1602	1610	survival	T052	C0038952
27994293	1612	1622	expression	T045	C1171362
27994293	1623	1627	MUM1	T116,T123	C0299544
27994293	1650	1656	impact	T080	C4049986
27994293	1664	1679	disease outcome	T033	C0679250
27994293	1689	1693	year	T079	C0439234
27994293	1694	1702	survival	T052	C0038952